Citations 0
Editor's Correspondence
February 25, 2002

New Approaches to Diagnosis and Management of Unstable Angina and Non–ST Segment Elevation Myocardial Infarction: Controversial Data

Author Affiliations

Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002

Arch Intern Med. 2002;162(4):485-486. doi:

We read with interest the report by O'Rourke et al,1 and there are some controversial data that are important to analyze. Reading this report, one could think that only one product of low-molecular-weight (LMW) heparin (enoxaparin sodium) is available in the treatment of acute coronary syndromes or that enoxaparin is better than the other LMW heparin products. However, there are 3 available LMW heparin products for this treatment (dalteparin, nadroparin, and enoxaparin), and there are no differences in their applications according to the current guidelines of cardiology.2

First Page Preview View Large
First page PDF preview
First page PDF preview